• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Stent wars: Researchers report a tie, of sorts, for Medtronic’s Resolute and Abbott’s Xience V DES

Stent wars: Researchers report a tie, of sorts, for Medtronic’s Resolute and Abbott’s Xience V DES

July 3, 2013 By Sony Salzman

Stent wars: Study equates Medtronic's Resolute and Abbott's Xience V drug-eluting stent

A study that compared drug-eluting stents from a pair of the industry’s heaviest hitters, Medtronic (NYSE:MDT) and Abbott (NYSE:ABT), concluded that both companies’ devices resulted in very similar clinical outcomes for patients.

The 2-year results of the TWENTE clinical trial, which compared Medtronic’s Resolute zotarolimus-eluting stent to Abbott’s Xience V everolimus-eluting stent, showed no real difference between the 2 in terms of target vessel failure, a key factor in cardiac death.

However, the 2 stents did differ slightly. Patients with Medtronic’s device had to be re-treated more often (experienced a higher target lesion revascularization), and patients with Abbott’s device were more likely to suffer cardiac death. Study authors noted that these differences led to overall endpoints that were statistically similar.

The trial randomly assorted 1,391 patients into 2 treatment arms, and the most recent 2-year data was published in Journal of the American College of Cardiology. TWENTE was also designed to learn more about these stents compared to older stents, such as  Boston Scientific’s  (NYSE:BSX) Taxus and Cordis’ Cypher, which contain a polymer that can led to inflammation after long-term use.

Now that Johnson & Johnson‘s (NYSE:JNJ) Cordis subsidiary has ceded the coronary stent market to its rivals, Abbott, Boston Scientific and Medtronic are locked in a 3-way battle to dominate the sector.

In the U.S. market, Abbott in January 2013 landed FDA approval for its Xience Xpedition coronary stent and Medtronic won expanded approval for Resolute Integrity the following month.

Filed Under: Drug-Eluting Stents, News Well Tagged With: Abbott, Boston Scientific, Clinical Trials, Cordis Corp., Johnson and Johnson, Minnesota, Stent Wars

More recent news

  • A new way to monitor glucose: Glucotrack explains 3-year CBGM implant technology
  • Dexcom continues advances in AI for CGM, type 2 diabetes awareness
  • Tandem continues to deliver more options, benefits for those with diabetes
  • Breaking: Sequel to launch twiist automated insulin delivery system next month
  • Dexcom shares U.S. report on CGM benefits for type 2 diabetes

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy